Management of Pulmonary Arterial Hypertension

作者: Vallerie V. McLaughlin , Sanjiv J. Shah , Rogerio Souza , Marc Humbert

DOI: 10.1016/J.JACC.2015.03.540

关键词:

摘要: Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung chronic thromboembolic disease. arterial (PAH) an uncommon disease characterized by progressive remodeling the distal pulmonary arteries, resulting in elevated vascular resistance and, eventually, right ventricular failure. Over past decades, knowledge basic pathobiology PAH its natural history, prognostic indicators, therapeutic options has exploded. A thorough evaluation patient critical to correctly characterize PH. Cardiac studies, echocardiography catheterization, are key elements assessment. Given multitude treatment currently available for PAH, assessment risk response therapy long-term management. This review also underscores unique situations, perioperative management, intensive care unit pregnancy, highlights importance collaborative through multidisciplinary approach.

参考文章(110)
Gurtner Hp, Aminorex and pulmonary hypertension. A review. Cor et vasa. ,vol. 27, pp. 160- 171 ,(1985)
Vallerie V. McLaughlin, Raymond L. Benza, Lewis J. Rubin, Richard N. Channick, Robert Voswinckel, Victor F. Tapson, Ivan M. Robbins, Horst Olschewski, Melvyn Rubenfire, Werner Seeger, Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension Journal of the American College of Cardiology. ,vol. 55, pp. 1915- 1922 ,(2010) , 10.1016/J.JACC.2010.01.027
Shao-Liang Chen, Feng-Fu Zhang, Jing Xu, Du-Jiang Xie, Ling Zhou, Thach Nguyen, Gregg W. Stone, Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension: The Single-Center, Prospective, First-in-Man PADN-1 Study (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension) Journal of the American College of Cardiology. ,vol. 62, pp. 1092- 1100 ,(2013) , 10.1016/J.JACC.2013.05.075
Marc Humbert, Marc Humbert, Martine Clozel, Alessandro Maresta, Endothelin receptor antagonists. Handbook of experimental pharmacology. ,vol. 218, pp. 199- 227 ,(2013) , 10.1007/978-3-642-38664-0_9
Xing-Xiang Wang, Fu-Rong Zhang, Yun-Peng Shang, Jun-Hui Zhu, Xu-Dong Xie, Qian-Min Tao, Jian-Hua Zhu, Jun-Zhu Chen, Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension: A Pilot Randomized Controlled Trial Journal of the American College of Cardiology. ,vol. 49, pp. 1566- 1571 ,(2007) , 10.1016/J.JACC.2006.12.037
GERALD SIMONNEAU, ROBYN J. BARST, NAZZARENO GALIE, ROBERT NAEIJE, STUART RICH, ROBERT C. BOURGE, ANNE KEOGH, RONALD OUDIZ, ADAANI FROST, SHELMER D. BLACKBURN, JAMES W. CROW, LEWIS J. RUBIN, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. ,vol. 165, pp. 800- 804 ,(2002) , 10.1164/AJRCCM.165.6.2106079
Roderick C. Deaño, Cherylanne Glassner-Kolmin, Melvyn Rubenfire, Adaani Frost, Scott Visovatti, Vallerie V. McLaughlin, Mardi Gomberg-Maitland, Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: The multicenter RePHerral study JAMA Internal Medicine. ,vol. 173, pp. 887- 893 ,(2013) , 10.1001/JAMAINTERNMED.2013.319
Olaf Mercier, Marc De Perrot, John Granton, Management of severe pulmonary arterial hypertension. Seminars in Respiratory and Critical Care Medicine. ,vol. 34, pp. 700- 713 ,(2013) , 10.1055/S-0033-1356460
David Montani, Rogerio Souza, Christoph Binkert, Walter Fischli, Gerald Simonneau, Martine Clozel, Marc Humbert, Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. ,vol. 131, pp. 101- 108 ,(2007) , 10.1378/CHEST.06-0682